180 related articles for article (PubMed ID: 34983074)
21. The effect of esomeprazole vs famotidine on aspirin/clopidogrel dual therapy after percutaneous coronary intervention.
Wu Y; Chen C; Luo Y; Yu W; Huang S; Lin D
Adv Clin Exp Med; 2019 Nov; 28(11):1519-1524. PubMed ID: 31660706
[TBL] [Abstract][Full Text] [Related]
22. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
25. Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease.
Connor DE; Ly K; Aslam A; Boland J; Low J; Jarvis S; Muller DW; Joseph JE
Platelets; 2016 Dec; 27(8):805-811. PubMed ID: 27310292
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
27. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Perzborn E; Heitmeier S; Laux V
J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):554-62. PubMed ID: 25848131
[TBL] [Abstract][Full Text] [Related]
28. Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy.
Hennigan BW; Good R; Adamson C; Parker WAE; Martin L; Anderson L; Campbell M; Serruys PW; Storey RF; Oldroyd KG
Platelets; 2022 Jan; 33(1):141-146. PubMed ID: 33356730
[TBL] [Abstract][Full Text] [Related]
29. Combined antiplatelet therapy: still a sweeping combination in cardiology.
Manolis AS; Manolis TA; Papadimitriou P; Koulouris S; Melita H
Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):136-67. PubMed ID: 23597106
[TBL] [Abstract][Full Text] [Related]
30. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel.
Cirillo P; Taglialatela V; Pellegrino G; Morello A; Conte S; Di Serafino L; Cimmino G
J Thromb Thrombolysis; 2020 Aug; 50(2):468-472. PubMed ID: 32335777
[TBL] [Abstract][Full Text] [Related]
31. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
Drouet L; Bal dit Sollier C; Henry P
Drugs; 2010 Nov; 70 Suppl 1():9-14. PubMed ID: 20977287
[TBL] [Abstract][Full Text] [Related]
32. Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy.
Bobbert P; Stellbaum C; Steffens D; Schütte C; Bobbert T; Schultheiss HP; Rauch U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):723-8. PubMed ID: 23135379
[TBL] [Abstract][Full Text] [Related]
33. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
34. Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study.
Gue YX; Memtsas V; Kanji R; Wellsted DM; Busby A; Smith M; Vilar E; Ryding A; Arachchillage DJ; Gorog DA
Thromb Res; 2024 Apr; 236():144-154. PubMed ID: 38447421
[TBL] [Abstract][Full Text] [Related]
35. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
[TBL] [Abstract][Full Text] [Related]
36. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.
Velik-Salchner C; Maier S; Innerhofer P; Kolbitsch C; Streif W; Mittermayr M; Praxmarer M; Fries D
Anesth Analg; 2009 Jun; 108(6):1747-54. PubMed ID: 19448196
[TBL] [Abstract][Full Text] [Related]
37. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Baber U; Zafar MU; Dangas G; Escolar G; Angiolillo DJ; Sharma SK; Kini AS; Sartori S; Joyce L; Vogel B; Farhan S; Gurbel P; Gibson CM; Fuster V; Mehran R; Badimon JJ
J Am Coll Cardiol; 2020 Feb; 75(6):578-586. PubMed ID: 32057371
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
Gremmel T; Koppensteiner R; Panzer S
PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
[TBL] [Abstract][Full Text] [Related]
39. Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease.
Jastrzebska M; Marcinowska Z; Oledzki S; Chelstowski K; Siennicka A; Klysz M; Clark JS
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552303
[TBL] [Abstract][Full Text] [Related]
40. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Wadowski PP; Eichelberger B; Kopp CW; Pultar J; Seidinger D; Koppensteiner R; Lang IM; Panzer S; Gremmel T
J Cardiovasc Transl Res; 2017 Aug; 10(4):359-367. PubMed ID: 28425039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
